SynthesisPloS one2018
First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis.
Synthesis in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Diagnostic performance of PAPP-A and β-hCG in early detection of gestational diabetes mellitus: a meta-analysis.Acta diabetologica · 2026Pooled it
- Prognostic Impact of Pregnancy-Associated Plasma Protein-A (PAPP-A) for Gestational Diabetes Mellitus (GDM): An Updated Systematic Review and Meta-Analysis of More Than 90 000 Pregnancies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Pooled it
- Maternal metabolic factors and the association with gestational diabetes: A systematic review and meta-analysis.Diabetes/metabolism research and reviews · 2022Pooled it
- Combined triple screening and BMI models for gestational diabetes prediction.Turkish journal of obstetrics and gynecology · 2026Article
- Comprehensive first-trimester targeted metabolomics for early prediction and understanding of GDM pathophysiology.Frontiers in molecular biosciences · 2026Article
- First-trimester biomarkers of gestational diabetes mellitus: A scoping review.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Evaluating the Predictive Value of HOMA-IR in Gestational Diabetes: A Case-Control Study from Romania.Diagnostics (Basel, Switzerland) · 2025Article
- Gestational diabetes mellitus - more than the eye can see - a warning sign for future maternal health with transgenerational impact.Frontiers in clinical diabetes and healthcare · 2025Review
- Early Prediction of Gestational Diabetes Mellitus and Insulin Therapy Requirement Using First-Trimester PAPP-A and Free β-hCG MoMs Levels: A Retrospective Case-Control Study.Journal of clinical medicine · 2024Article
- A first trimester prediction model and nomogram for gestational diabetes mellitus based on maternal clinical risk factors in a resource-poor setting.BMC pregnancy and childbirth · 2024Observational
- Comparative analysis of obstetric, perinatal, and neurodevelopmental outcomes following chorionic villus sampling and amniocentesis.Frontiers in medicine · 2024Article
- Associations between first-trimester screening biomarkers and maternal characteristics with gestational diabetes mellitus in Chinese women.Frontiers in endocrinology · 2024Article
- Placental Growth Factor and Pregnancy-Associated Plasma Protein-A as Potential Early Predictors of Gestational Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2023Review
- Study on the Relationship and Predictive Value of First-Trimester Pregnancy-Associated Plasma Protein-A, Maternal Factors, and Biochemical Parameters in Gestational Diabetes Mellitus: A Large Case-Control Study in Southern China Mothers.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Review
- Non-Assisted Hatching Trophectoderm Biopsy Does Not Increase The Risks of Most Adverse Maternal and Neonatal Outcome and May Be More Practical for Busy Clinics: Evidence From China.Frontiers in endocrinology · 2022Article
- Early Rise of Serum hCG in Gestational Diabetes Mellitus Women With Live Birth ThroughFrontiers in endocrinology · 2022Article
- The Role of Afamin and Other Trace Elements in the Prediction of GDM: a Tertiary Center Experience.Biological trace element research · 2021Article
- Placental Endocrine Activity: Adaptation and Disruption of Maternal Glucose Metabolism in Pregnancy and the Influence of Fetal Sex.International journal of molecular sciences · 2021Review
- Placental secretome characterization identifies candidates for pregnancy complications.Communications biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Biomarkers commonly assessed in prenatal screening have been associated with a number of adverse perinatal and birth outcomes. However, it is not clear whether first trimester measurements of prenatal screening biomarkers are associated with subsequent risk of gestational diabetes mellitus (GDM). We aimed to systematically review and statistically summarize studies assessing the relationship between first trimester prenatal screening biomarker levels and GDM development. We comprehensively searched PubMed/MEDLINE, EMBASE, CINAHL, and Scopus (from inception through January 2018) and manually searched the reference lists of all relevant articles. We included original, published, observational studies examining the association of first trimester pregnancy associated plasma protein-A (PAPP-A) and/or free β-human chorionic gonadotropin (free β-hCG) levels with GDM diagnosis. Mean differences were calculated comparing PAPP-A and free β-hCG multiples of median (MoM) levels between women who developed GDM and those who did not and were subsequently pooled using two-sided random-effects models. Our meta-analysis of 13 studies on PAPP-A and nine studies on free β-hCG indicated that first trimester MoM levels for both biomarkers were lower in women who later developed GDM compared to women who remained normoglycemic throughout pregnancy (MD -0.17; 95% CI -0.24, -0.10; MD -0.04; 95% CI -0.07-0.01). There was no evidence for between-study heterogeneity among studies on free β-hCG (I2 = 0%). A high level of between-study heterogeneity was detected among the studies reporting on PAPP-A (I2 = 90%), but was reduced after stratifying by geographic location, biomarker assay method, and timing of GDM diagnosis. Our meta-analysis indicates that women who are diagnosed with GDM have lower first trimester levels of both PAPP-A and free β-hCG than women who remain normoglycemic throughout pregnancy. Further assessment of the predictive capacity of these biomarkers within large, diverse populations is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.